Advertisement

gynäkologie + geburtshilfe

, Volume 23, Issue 6, pp 38–46 | Cite as

Update der S3-Leitlinie

Aktuelle Therapiestrategien beim primären Mammakarzinom

  • Jasmin Festl
  • Achim Wöckel
Zertifizierte Fortbildung
  • 17 Downloads

Zusammenfassung

In der aktualisierten S3-Leitlinie für die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms von Dezember 2017 haben sich auch Neuerungen für die Behandlung des frühen Brustkrebs’ ergeben. So hat sich vor allem im Hinblick auf das operative Vorgehen die Radikalität verringert. Die erweiterten Möglichkeiten der Bestrahlung und systemischen Therapie in der adjuvanten Situation sind ebenfalls in die neuen Empfehlungen eingegangen.

Literatur

  1. 1.
    Robert-Koch-Institut. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg). Krebs in Deutschland für 2013/2014. 2017. 11. Ausg. Berlin; 2017Google Scholar
  2. 2.
    Leitlinienprogramm Onkologie der AWMF, Deutschen Krebsgesellschaft und Deutschen Krebshilfe (Hrsg.) S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms (Langversion 4.0 — Dezember 2017, AWMF-Registernummer: 032-045OL). 2017.http://www.awmf.org/uploads/tx_szleitlinien/032-045OLl_S3_Mammakarzinom_2017-12.pdf, abgerufen am 16.05.18
  3. 3.
    Buchholz TA et al. Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline. J Clin Oncol. 2014;32:1502–6CrossRefPubMedGoogle Scholar
  4. 4.
    Voogd AC et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol. 2001;19:1688–97CrossRefPubMedGoogle Scholar
  5. 5.
    Fisher B, Anderson S. Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials. National Surgical Adjuvant Breast and Bowel Project. World J Surg. 1994;18:63–9CrossRefPubMedGoogle Scholar
  6. 6.
    De La Cruz L et al. Overall Survival, Disease-Free Survival, Local Recurrence, and Nipple-Areolar Recurrence in the Setting of Nipple-Sparing Mastectomy: A Meta-Analysis and Systematic Review. Ann Surg Oncol. 2015;22:3241–9CrossRefPubMedGoogle Scholar
  7. 7.
    Piper M et al. Total skin-sparing mastectomy: a systematic review of oncologic outcomes and postoperative complications. Ann Plast Surg. 2013;70:435–7CrossRefPubMedGoogle Scholar
  8. 8.
    Arbeitsgemeinschaft für ästhetische, plastische und wiederherstellende Operationsverfahren in der Gynäkologie e.V. (Hrsg.). Deutsche Gesellschaft für Gynäkologie und Geburtshilfe, Leitlinienprogramm — Brustrekonstruktion mit Eigengewebe. AWMF-Registernummer 015/075, Leitlinienklasse S3, Stand März 2015, Version 1.0. 2015. http://www.awmf.org/uploads/tx_szleitlinien/015-075l_S3_Brustrekonstruktion_Eigengewebe_2015-04.pdf, abgerufen am 16.05.18
  9. 9.
    Hoffmann J, Wallwiener D. Classifying breast cancer surgery: a novel, complexity-based system for oncological, oncoplastic and reconstructive procedures, and proof of principle by analysis of 1225 operations in 1166 patients. BMC Cancer. 2009;9:108CrossRefPubMedGoogle Scholar
  10. 10.
    Andersson Y. et al. Axillary recurrence rate 5 years after negative sentinel node biopsy for breast cancer. Br J Surg. 2012;99:226–31CrossRefPubMedGoogle Scholar
  11. 11.
    Giuliano AE et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569–75CrossRefPubMedGoogle Scholar
  12. 12.
    Giuliano AE et al. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial. Ann Surg. 2016;264:413–20CrossRefPubMedGoogle Scholar
  13. 13.
    Classe JM et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol. 2009;27:726–32CrossRefPubMedGoogle Scholar
  14. 14.
    Boughey JC et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455–61CrossRefPubMedGoogle Scholar
  15. 15.
    Kuehn T et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14:609–18CrossRefPubMedGoogle Scholar
  16. 16.
    Trentin C et al. Predictors of invasive breast cancer and lymph node involvement in ductal carcinoma in situ initially diagnosed by vacuum-assisted breast biopsy: experience of 733 cases. Breast. 2012;21:635–40CrossRefGoogle Scholar
  17. 17.
    Chin-Lenn L et al. Predictors of treatment with mastectomy, use of sentinel lymph node biopsy and upstaging to invasive cancer in patients diagnosed with breast ductal carcinoma in situ (DCIS) on core biopsy. Ann Surg Oncol. 2014;21:66–73CrossRefGoogle Scholar
  18. 18.
    Virnig BA et al. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010;102:170–8CrossRefGoogle Scholar
  19. 19.
    Narod SA et al. Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ. JAMA Oncol. 2015;1:888–96CrossRefGoogle Scholar
  20. 20.
    Shamliyan T et al. Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ. J Natl Cancer Inst Monogr. 2010;2010:121–9CrossRefPubMedGoogle Scholar
  21. 21.
    Marinovich ML et al. The Association of Surgical Margins and Local Recurrence in Women with Ductal Carcinoma In Situ Treated with Breast-Conserving Therapy: A Meta-Analysis. Ann Surg Oncol. 2016;23:3811–21CrossRefPubMedGoogle Scholar
  22. 22.
    Rudloff U et al. The influence of margin width and volume of disease near margin on benefit of radiation therapy for women with DCIS treated with breast-conserving therapy. Ann Surg. 2010;251:583–91CrossRefPubMedGoogle Scholar
  23. 23.
    Lyman GH et al. Sentinel lymph node biopsy for patients with earlystage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014;32:1365–83CrossRefPubMedGoogle Scholar
  24. 24.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707–16CrossRefGoogle Scholar
  25. 25.
    Haviland JS et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14:1086–94CrossRefPubMedGoogle Scholar
  26. 26.
    Whelan TJ et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362:513–20CrossRefPubMedGoogle Scholar
  27. 27.
    Bartelink H et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015;16:47–56CrossRefPubMedGoogle Scholar
  28. 28.
    Warnberg F et al. Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial. J Clin Oncol. 2014;32:3613–8CrossRefPubMedGoogle Scholar
  29. 29.
    Goodwin A et al. Post-operative radiotherapy for ductal carcinoma in situ of the breast. Cochrane Database Syst Rev. 2013;11:CD000563Google Scholar
  30. 30.
    Goldhirsch A et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol. 2011;22:1736–47CrossRefPubMedGoogle Scholar
  31. 31.
    Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389:1134–50CrossRefPubMedGoogle Scholar
  32. 32.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717CrossRefGoogle Scholar
  33. 33.
    Sparano JA et al. Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. J Clin Oncol. 2015;33:2353–60CrossRefPubMedGoogle Scholar
  34. 34.
    Bria E et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer. 2006;106:2337–44CrossRefPubMedGoogle Scholar
  35. 35.
    Martin M et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst. 2008;100:805–14CrossRefPubMedGoogle Scholar
  36. 36.
    Moebus V et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol. 2010;28:2874–80CrossRefPubMedGoogle Scholar
  37. 37.
    Jones S et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. J Clin Oncol. 2009;27:1177–83CrossRefPubMedGoogle Scholar
  38. 38.
    von Minckwitz G et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat. 2011;125:145–56CrossRefGoogle Scholar
  39. 39.
    Cortazar P et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164–72CrossRefGoogle Scholar
  40. 40.
    Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84CrossRefPubMedGoogle Scholar
  41. 41.
    Moja L et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012;4:CD006243Google Scholar
  42. 42.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–84CrossRefGoogle Scholar
  43. 43.
    Colleoni M et al. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19:127–38CrossRefPubMedGoogle Scholar
  44. 44.
    Davies C et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor- positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805–16CrossRefPubMedGoogle Scholar
  45. 45.
    Burstein HJ et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014;32:2255–69CrossRefPubMedGoogle Scholar
  46. 46.
    Pagani O. et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371:107–18CrossRefPubMedGoogle Scholar
  47. 47.
    Blok EJ et al. Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05). J Natl Cancer Inst. 2018;110(1).CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Frauenklinik und Poliklinik, Universitätsklinikum WürzburgWürzburgDeutschland

Personalised recommendations